Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.
Park W, Suh CH, Shim SC, Molina FFC, Jeka S, Medina-Rodriguez FG, Hrycaj P, Wiland P, Lee EY, Shesternya P, Kovalenko V, Myasoutova L, Stanislav M, Radominski S, Lim MJ, Choe JY, Lee SJ, Lee SY, Kim SH, Yoo DH.
Park W, et al. Among authors: lee ey, lee sj, lee sy.
BioDrugs. 2017 Aug;31(4):369-377. doi: 10.1007/s40259-017-0233-6.
BioDrugs. 2017.
PMID: 28600696
Free PMC article.
Clinical Trial.